Effect of TU-100 in Patients With Functional Constipation

NCT01348152 | Completed Phase 2 DMC

• 1 other identifier: TU100CPT3
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study is to evaluate the improvement in the severity of constipation (from Baseline to Day 28), determined by the constipation severity instrument (CSI) score \[1\], compared to placebo, following a total daily oral dose of 15 g TU-100 administered for 28 consecutive days in adult subjects with functional constipation.

Conditions

Functional Constipation

Keywords

Gastric Emptying

Outcome Measures

Primary Outcomes (1)

• Change from baseline to Day 28 in CSI total score

  Up to 10 weeks

Secondary Outcomes (5)

• Change from baseline in GI transit time measured by SmartPill capsule.

  Up to 10 weeks

• Change from baseline to Day 28 in CRQOL total score.

  Up to 10 weeks

• Changes from baseline in stool frequency, stool consistency, severity of straining, and completeness of evacuation determined from entries in the bowel pattern diary.

  Up to 10 weeks

• Change from baseline to Day 28 in CSI subscale scores.

  Up to 10 weeks

• Change from baseline to Day 28 in CRQOL subscale scores.

  Up to 10 weeks

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Placebo TID

Drug: Placebo

DAIKENCHUTO (TU-100) 15 g/day

EXPERIMENTAL

TU-100 5g TID

Drug: DAIKENCHUTO (TU-100)

Interventions

DAIKENCHUTO (TU-100) DRUG

Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.

DAIKENCHUTO (TU-100) 15 g/day

Placebo DRUG

Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.

Placebo

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have severity of constipation in CSI score of 25 to 74 points.
• Have the ability to orally ingest study medication, TU-100, and the SmartPill capsule.
• Be male or female aged between 18 and 80 years old, inclusive.
• Provide written informed consent before participation in the study after full explanations of the study purpose and procedures.
• If a female is of childbearing potential and sexually active:
• She must agree to practice a highly effective method of birth control, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, during their participation in the trial and for 4 weeks after receiving the last dose of study drug
• She must have a negative serum pregnancy test before randomization.
• If a male is sexually active with a female of childbearing potential:
• He must agree to use a double barrier of birth control during the study and for 4 weeks after receiving the last dose of study drug.
• He must not donate sperm during the study and for 4 weeks after receiving the last dose of study drug.

You may not qualify if:

• Presence of strictures, fistulas, or physiological or mechanical bowel obstruction.
• Presence of implanted or portable electro-mechanical medical devices.
• History of gastric bezoar or swallowing disorders.
• History of gastrointestinal surgery within 3 months of screening.
• History of bowel resection.
• Current pregnancy or lactation.
• History of clinically significant alcohol or drug abuse within a year of screening.
• Have any other condition that might adversely affect capacity to participate in this study, including liver disorders (with serum alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\] levels exceeding 2.5 times the upper limit of normal \[ULN\]), kidney disorders, heart failure, blood disorders, or metabolic disorders.
• Be diagnosed with cancer, ulcerative colitis, Crohn's disease, diverticulitis, scleroderma, Hirschsprung's disease, Chagas' disease, multiple sclerosis, Parkinson's disease, stroke, paraplegia, quadriplegia, insulin-dependent diabetes mellitus, untreated hypothyroidism, or any other systemic or psychiatric disorder which may, in the opinion of the investigator, interfere with the evaluation of TU-100.
• Be taking any medication as follows: anticholinergic agents/medications with anticholinergic effect (list of prohibited drugs attached in Appendix G; antidepressants are permissible if the patient's symptoms are stable, and the doses are NOT changed during the course of the study), warfarin, prokinetics (i.e., Domperidone, Metoclopramide), narcotic analgesics, or any agent that might interfere with the evaluation of TU-100 in the opinion of the investigator.
• Have a history of allergic reaction or hypersensitivity to ginseng, ginger, and Sichuan pepper.
• Have severe dysphagia to food or pills.
• Have participated in any other clinical study within 30 days before enrolling in this study.
• Be unsuitable for participation in this trial for any reason, according to the investigator.

Sponsors & Collaborators

• Tsumura USA: lead
• Cato Research: collaborator

Study Sites (1)

Colon and Rectal Surgery Associates

Minneapolis, Minnesota, 55407, United States

Location

MeSH Terms

Interventions

dai-kenchu-to; 12,13-dihydro-N-methyl-6,11,13-trioxo-5H-benzo(4,5)cyclohepta(1,2-b)naphthalen-5,12-imine

Study Officials

• Anders F Mellgren, MD, PhD

  Colon and Rectal Surgery Associates

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 3, 2011
• First Posted: May 5, 2011
• Study Start: September 1, 2011
• Primary Completion: July 1, 2013
• Study Completion: July 1, 2013
• Last Updated: September 17, 2013

Record last verified: 2013-09

Locations

US (1)